 |
市場調查報告書
商品編碼
1735555
潰瘍性大腸炎市場 - 全球和區域分析：依藥物類別和地區 - 分析和預測（2025年至2035年）Ulcerative Colitis Market - A Global and Regional Analysis: Focus on Drug Class and Region - Analysis and Forecast, 2025-2035 |
||||||
潰瘍性大腸炎是一種以結腸和直腸發炎為特徵的慢性發炎性腸道疾病。
潰瘍性大腸炎由於其表現形式多樣且復發難以預測，因此在治療上面臨獨特的挑戰。在預測期內，對單株抗體和先進的免疫調節藥物等生物製藥的日益關注預計將推動全球市場的發展。
市場依藥物類別細分，其中抗TNF-α藥物、白細胞介素拮抗劑、皮質類固醇以及JAK抑制劑等其他治療藥物在滿足潰瘍性大腸炎患者的多樣化需求方面佔據領先地位。每類藥物發揮不同的治療效果，有助於制定針對性較強的疾病管理方案。
由於完善的醫療保健基礎設施、較高的認知度以及政府對發炎性腸道疾病研究的資助不斷增加，北美預計將繼續引領全球潰瘍性大腸炎市場。
需求－促進因素與限制因素
推動全球潰瘍性大腸炎市場需求的因素有：
- 潰瘍性大腸炎盛行率的不斷上升導致對有效治療和管理方案的需求不斷增加。
- 診斷和治療方法的創新改善疾病管理，推動市場擴張。
- 潰瘍性大腸炎生物製藥和免疫調節藥物的開發提高治療效果，推動市場成長。
限制因素
- 潰瘍性大腸炎治療高成本
產品/創新策略：全球潰瘍性大腸炎市場經歷藥物配方和病患照護策略的創新。企業可以利用本報告發現新的產品開發機會，包括個人化治療方法、先進的生物療法以及目的是改善患者預後的非侵入性治療方案。
競爭策略：為了保持競爭力，公司應致力於提高現有療法的療效，探索聯合治療，並提供經濟高效的解決方案。策略夥伴關係、市場區隔以及利用監管發展也將在聯合治療市場（尤其是在新興地區）保持強勢地位方面發揮重要作用。
主要市場參與企業及競爭格局
本報告中提供的公司簡介是基於關鍵專家的意見，並分析了公司覆蓋範圍、產品系列和市場滲透率。全球潰瘍性大腸炎市場的主要企業包括製藥公司，在市場影響方面佔有重要佔有率。
本報告研究了全球潰瘍性大腸炎市場，概述了市場以及藥物類別、地區和參與市場的公司概況的趨勢。
目錄
執行摘要
第1章 全球潰瘍性大腸炎市場：產業展望
- 市場概況與生態系統
- 潰瘍性大腸炎流行病學分析
- 依地區
- 市場趨勢
- 臨床試驗
- 依階段
- 監理格局分析
- 美國法律要求與框架
- 歐盟法律要求和框架
- 亞太地區的法律要求與框架
- 市場動態
- 影響分析
- 市場促進因素
- 市場限制
- 市場機會
第2章 全球潰瘍性大腸炎市場（依藥物類別），百萬美元，2023-2035年
- 抗TNFα藥物
- 白細胞介素拮抗劑
- 其他
第3章 全球潰瘍性大腸炎市場（依地區），百萬美元，2023-2035年
- 北美洲
- 歐洲
- 亞太地區
第4章 全球潰瘍性大腸炎市場的競爭基準化分析與公司概況
- 競爭格局
- 各公司主要策略及發展
- 主要進展
- 公司簡介
- Takeda Pharmaceuticals
- Johnson & Johnson（Janssen Biotech）
- Boehringer Ingelheim
- Eli Lilly and Company
- Pfizer, Inc.
- AbbVie
第5章 調查方法
Global Ulcerative Colitis Market Industry Overview
Ulcerative colitis is a chronic inflammatory bowel disease characterized by inflammation of the colon and rectum. It presents unique challenges in treatment due to its variable symptoms and unpredictable flare-ups. The increasing focus on biologic treatments, including monoclonal antibodies and advanced immunomodulators, is expected to drive the global market forward during the forecast period.
Market Segmentation:
Segmentation 1: By Drug Class
- Anti-TNF a Agents
- Interleukin Antagonists
- Others
The market is segmented by drug class, with Anti-TNF a agents, interleukin antagonists, and other therapies like corticosteroids and JAK inhibitors leading the way in addressing the diverse needs of ulcerative colitis patients. Each class offers distinct therapeutic benefits, contributing to a more nuanced approach to disease management.
Segmentation 2: By Region
- North America
- Europet
- Asia-Pacific
North America is expected to continue leading the global ulcerative colitis market due to well-established healthcare infrastructure, higher awareness, and increasing government funding for inflammatory bowel disease research.
Demand - Drivers and Limitations
Following are the demand drivers for the global ulcerative colitis market:
- The growing incidence of ulcerative colitis is driving demand for effective treatments and management options
- Innovations in diagnostics and therapies are improving disease management and supporting market expansion
- Ongoing developments in biologics and immunomodulators for ulcerative colitis are enhancing treatment efficacy and driving market growth
Limitations:
- The high cost for ulcerative colitis treatment
How Can This Report Add Value to an Organization?
Product/Innovation Strategy: The global ulcerative colitis market is seeing innovations in drug formulations and patient care strategies. Companies can leverage this report to identify new opportunities for product development, such as personalized treatment approaches, advanced biologic therapies, and non-invasive treatment options to improve patient outcomes.
Competitive Strategy: To stay competitive, companies should focus on enhancing the efficacy of existing treatments, exploring combination therapies, and offering cost-effective solutions. Strategic partnerships, market segmentation, and leveraging regulatory advancements will also play a crucial role in maintaining a strong market position, especially in emerging regionsbination therapies, .
Key Market Players and Competition Synopsis
The companies profiled in this report are based on inputs from primary experts, analyzing company coverage, product portfolio, and market penetration. The leading players in the global ulcerative colitis market comprise pharmaceutical companies, who hold significant shares of the market presence.
Some of the prominent names established in this market are:
- Johnson & Johnson (Janssen Biotech)
- AbbVie
- Takeda Pharmaceuticals
- Pfizer, Inc.
- Boehringer Ingelheim
- Eli Lilly and Company
Table of Contents
Executive Summary
Scope of Study
Product Definition
Inclusion and Exclusion Criteria
1. Global Ulcerative Colitis Market: Industry Outlook
- 1.1 Market Overview and Ecosystem
- 1.2 Epidemiological Analysis of Ulcerative Colitis
- 1.2.1 By Region
- 1.3 Market Trends
- 1.4 Clinical Trials
- 1.4.1 By Phase
- 1.5 Regulatory Landscape Analysis
- 1.5.1 Legal Requirement and Framework in U.S.
- 1.5.2 Legal Requirement and Framework in E.U.
- 1.5.3 Legal Requirement and Framework in Asia-Pacific
- 1.6 Market Dynamics
- 1.6.1 Impact Analysis
- 1.6.2 Market Drivers
- 1.6.3 Market Restraints
- 1.6.4 Market Opportunities
2. Global Ulcerative Colitis Market, by Drug Class, $Million, 2023-2035
- 2.1 Anti-TNF a Agents
- 2.2 Interleukin Antagonists
- 2.3 Others
3. Global Ulcerative Colitis Market (by Region), $Million, 2023-2035
- 3.1 North America
- 3.1.1 Key Findings
- 3.1.2 Market Dynamics
- 3.1.3 Market Sizing and Forecast
- 3.1.3.1 North America Ulcerative Colitis Market (by Country)
- 3.1.3.1.1 U.S.
- 3.1.3.1 North America Ulcerative Colitis Market (by Country)
- 3.2 Europe
- 3.2.1 Key Findings
- 3.2.2 Market Dynamics
- 3.2.3 Market Sizing and Forecast
- 3.2.3.1 Europe Ulcerative Colitis Market (by Country)
- 3.2.3.1.1 Germany
- 3.2.3.1.2 France
- 3.2.3.1.3 Italy
- 3.2.3.1.4 U.K.
- 3.2.3.1 Europe Ulcerative Colitis Market (by Country)
- 3.3 Asia-Pacific
- 3.3.1 Key Findings
- 3.3.2 Market Dynamics
- 3.3.3 Market Sizing and Forecast
- 3.3.3.1 Asia-Pacific Ulcerative Colitis Market (by Country)
- 3.3.3.1.1 Japan
- 3.3.3.1 Asia-Pacific Ulcerative Colitis Market (by Country)
4. Global Ulcerative Colitis Market Competitive Benchmarking and Company Profiles
- 4.1 Competitive Landscape
- 4.1.1 Key Strategies and Developments by Company
- 4.1.1.1 Funding Activities
- 4.1.1.2 Mergers and Acquisitions
- 4.1.1.3 Regulatory Approvals
- 4.1.1.4 Partnerships, Collaborations and Business Expansions
- 4.1.2 Key Developments Analysis
- 4.1.1 Key Strategies and Developments by Company
- 4.2 Company Profiles
- 4.2.1 Takeda Pharmaceuticals
- 4.2.1.1 Company Overview
- 4.2.1.2 Product Portfolio
- 4.2.1.3 Target Customers/End Users
- 4.2.1.4 Key Personnels
- 4.2.1.5 Analyst View
- 4.2.2 Johnson & Johnson (Janssen Biotech)
- 4.2.2.1 Company Overview
- 4.2.2.2 Product Portfolio
- 4.2.2.3 Target Customers / End Users
- 4.2.2.4 Key Personnels
- 4.2.2.5 Analyst View
- 4.2.3 Boehringer Ingelheim
- 4.2.3.1 Company Overview
- 4.2.3.2 Product Portfolio
- 4.2.3.3 Target Customers / End Users
- 4.2.3.4 Key Personnels
- 4.2.3.5 Analyst View
- 4.2.4 Eli Lilly and Company
- 4.2.4.1 Company Overview
- 4.2.4.2 Product Portfolio
- 4.2.4.3 Target Customers / End Users
- 4.2.4.4 Key Personnels
- 4.2.4.5 Analyst View
- 4.2.5 Pfizer, Inc.
- 4.2.5.1 Company Overview
- 4.2.5.2 Product Portfolio
- 4.2.5.3 Target Customers / End Users
- 4.2.5.4 Key Personnels
- 4.2.5.5 Analyst View
- 4.2.6 AbbVie
- 4.2.6.1 Company Overview
- 4.2.6.2 Product Portfolio
- 4.2.6.3 Target Customers / End Users
- 4.2.6.4 Key Personnels
- 4.2.6.5 Analyst View
- 4.2.1 Takeda Pharmaceuticals
5. Research Methodology
List of Figures
- Figure: Global Ulcerative Colitis Market Coverage
- Figure: Global Ulcerative Colitis Market, Key Trends, Impact Analysis
- Figure: Global Ulcerative Colitis Market, Competitive Landscape
List of Tables
- Table: Global Ulcerative Colitis Market, Dynamics, Impact Analysis
- Table: Global Ulcerative Colitis Market, Regulatory Landscape
- Table: Global Ulcerative Colitis Market, (by Drug Class), $Million, 2023-2035Regulatory Landscape
- Table: Global Ulcerative Colitis Market, (by Region), $Million, 2023-2035
